AI-ACCELERATED DRUG DISCOVERY

Receptor-type tyrosine-protein phosphatase alpha

Explore its Potential with AI-Driven Innovation
Predicted by Alphafold

Receptor-type tyrosine-protein phosphatase alpha - Focused Library Design

Available from Reaxense

This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Receptor-type tyrosine-protein phosphatase alpha including:

1. LLM-powered literature research

Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Receptor-type tyrosine-protein phosphatase alpha therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.

 Fig. 1. Preliminary target research workflow

2. AI-Driven Conformational Ensemble Generation

Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Receptor-type tyrosine-protein phosphatase alpha, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.

 Fig. 2. AI-powered molecular dynamics simulations workflow

3. Binding pockets identification and characterization

We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.

 Fig. 3. AI-based binding pocket detection workflow

4. AI-Powered Virtual Screening

Our ecosystem is equipped to perform AI-driven virtual screening on Receptor-type tyrosine-protein phosphatase alpha. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Receptor-type tyrosine-protein phosphatase alpha. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.

 Fig. 4. The screening workflow of Receptor.AI

Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.

The focused library for Receptor-type tyrosine-protein phosphatase alpha includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Receptor-type tyrosine-protein phosphatase alpha

partner:

Reaxense

upacc:

P18433

UPID:

PTPRA_HUMAN

Alternative names:

-

Alternative UPACC:

P18433; A8K2G8; D3DVX5; Q14513; Q7Z2I2; Q96TD9

Background:

Receptor-type tyrosine-protein phosphatase alpha plays a pivotal role in integrin-mediated focal adhesion formation. It orchestrates the assembly of key signaling molecules such as BCAR3, BCAR1, and CRK at focal adhesions, facilitating SRC-mediated phosphorylation of BRAC1. This cascade activates PAK and the small GTPases RAC1 and CDC42, crucial for cell movement and signaling.

Therapeutic significance:

Understanding the role of Receptor-type tyrosine-protein phosphatase alpha could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways offers a promising avenue for targeting diseases where cell adhesion and migration are factors.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.